Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-epileptic drug use and subsequent degenerative dementia occurrence.
Ikegaya N, Nakamura H, Takayama Y, Miyake Y, Hayashi T, Sonoda M, Sato M, Tateishi K, Suenaga J, Takaishi M, Kitazawa Y, Kunii M, Abe H, Miyazaki T, Arai T, Iwasaki M, Abe T, Yamamoto T. Ikegaya N, et al. Among authors: arai t. Alzheimers Dement (N Y). 2024 Sep 10;10(3):e70001. doi: 10.1002/trc2.70001. eCollection 2024 Jul-Sep. Alzheimers Dement (N Y). 2024. PMID: 39257557 Free PMC article.
What happens if your colleague was the first person to notice that you have young-onset dementia?
Edahiro A, Okamura T, Arai T, Ikeuchi T, Ikeda M, Utsumi K, Ota H, Kakuma T, Kawakatsu S, Konagaya Y, Suzuki K, Tanimukai S, Miyanaga K, Awata S. Edahiro A, et al. Among authors: arai t. Geriatr Gerontol Int. 2024 Jan;24(1):176-178. doi: 10.1111/ggi.14733. Epub 2023 Nov 21. Geriatr Gerontol Int. 2024. PMID: 37990422 Free PMC article. No abstract available.
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCC.
Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Nakamura Y, Yoshida O, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Matono T, et al. Among authors: arai t. J Gastroenterol Hepatol. 2025 Jan 22. doi: 10.1111/jgh.16884. Online ahead of print. J Gastroenterol Hepatol. 2025. PMID: 39844393
Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma.
Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Hirooka M, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T. Naganuma A, et al. Among authors: arai t. Cancer Med. 2025 Jan;14(2):e70618. doi: 10.1002/cam4.70618. Cancer Med. 2025. PMID: 39840727 Free PMC article.
Effects of stocking density on growth performance, digestive enzyme activity, biochemical composition, and economic efficiency of a new strain of Oreochromis niloticus reared in cage culture system at Sindh Pakistan.
Hassan HU, Ali A, Wattoo J, Sohail M, Raza MA, Hassan SA, Kanwal R, Kabir M, Rafiq N, Manoharadas S, Khan MR, Arai T. Hassan HU, et al. Among authors: arai t. Food Sci Nutr. 2024 Dec 10;13(1):e4238. doi: 10.1002/fsn3.4238. eCollection 2025 Jan. Food Sci Nutr. 2024. PMID: 39803227 Free PMC article.
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T; Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hatanaka T, et al. Among authors: arai t. J Gastroenterol Hepatol. 2025 Jan 6. doi: 10.1111/jgh.16871. Online ahead of print. J Gastroenterol Hepatol. 2025. PMID: 39762722
4,178 results